Derick appears in C&EN

Our Ph.D. student Derick Jones represented the group at this year’s NOBCChE conference. His photo appeared in C&EN! (C&EN Volume 95 Issue…

Improvement by ten orders of magnitude

A press release from our partner company reports that our newest generation of cancer-fighting drugs is ten billion times more potent than…

Katsuya “Lex” Colon wins an award

Lex’s excellence in the research lab was recognized with the awarding of the Lilian Nile Undergraduate Research Assistantship at the 2017 Homecoming….

Preclinical news: destroying brain cancer!

In preclinical results, our lead cancer drug, TLD-1433, has been shown to destroy the human brain cancer glioblastoma multiforme (GBM) when activated…

Our research article made the cover of Photochemistry and Photobiology!

Our article Novel Osmium-based Coordination Complexes as Photosensitizers for Panchromatic Photodynamic Therapy is the feature article in the journal Photochemistry and Photobiology….

Independent validation of our cancer drugs

A recent publication in Inorganic Chemistry uses computational tools to validate the TypeI/TypeII dual mode activity in our cancer drugs. See our…

Second patent granted for Ruthenium-based PDT cancer drugs

A second patent (US #9,676,806) has been granted for our high-potency photodynamic cancer drugs.

Patent granted!

Our lead anti-cancer drug has been granted US patent number 9,345,769.

Most cited paper

Our 2013 article [14] made the list of most cited publications in Photodiagnosis and Photodynamic Therapy for the past 5 years!

A new home!

The McFarland group is now up and running at the University of North Carolina at Greensboro. Your days are numbered, cancer!!